TABLE 2.

Summary of adverse events after the administration of GST-HG141, according to each dose cohort (n = 92)^a

Preferred term	SAD									MAD
	50 mg (N = 8), n (%)	100 mg (N = 8), n (%)	200 mg (N = 8), n (%)	300 mg, fasted (N = 16), n (%)	300 mg, fed (N = 16), n (%)	300 mg, overall (N = 16), n (%)	400 mg (N = 8), n (%)	500 mg (N = 8), n (%)	Placebo (N = 12), n (%)	100 mg BID (N = 10), n (%)	200 mg BID (N = 10), n (%)	Placebo (N = 4), n (%)
Over with TEAE	0	2 (25.0)	0	0	2 (12.5)	2 (12.5)	6 (75.0)	2 (25.0)	4 (33.3)	2 (20.0)	3 (30.0)	2 (50.0)
Serum creatinine increased	0	0	0	0	0	0	2 (25.0)	0	0	0	1 (10.0)	0
ALT increased	0	0	0	0	0	0	1 (12.5)	0	0	0	0	0
AST increased	0	0	0	0	0	0	1 (12.5)	0	0	1 (10.0)	0	0
CK increased	0	0	0	0	0	0	1 (12.5)	0	0	1 (10.0)	1 (10.0)	0
CK-MB increased	0	0	0	0	0	0	0	0	0	1 (10.0)	0	0
Serum bilirubin increased	0	0	0	0	0	0	1 (12.5)	0	0	0	0	1 (25.0)
Hypertriglyceridemia	0	0	0	0	0	0	0	1 (12.5)	0	0	1 (10.0)	0
Hypoalbuminemia	0	0	0	0	0	0	0	0	2 (16.7)	0	0	0
Hyperuricaemia	0	0	0	0	0	0	0	0	0	1 (10.0)	0	0
Neutrophil count increased	0	0	0	0	1 (6.3)	1 (6.3)	0	0	0	0	0	0
Neutrophil count decreased	0	1 (12.5)	0	0	0	0	0	0	0	0	1 (10.0)	0
Lymphocyte count decreased	0	0	0	0	1 (6.3)	1 (6.3)	0	0	0	0	0	0
WBC count increased	0	0	0	0	1 (6.3)	1 (6.3)	0	0	0	0	0	0
WBC count decreased	0	1 (12.5)	0	0	0	0	0	0	0	0	1 (10.0)	0
Urinary RBC positive	0	1 (12.5)	0	0	0	0	0	0	0	0	0	0
Urinary sediments positive	0	0	0	0	0	0	0	0	1 (8.3)	0	0	0
Urinary tract infection	0	0	0	0	0	0	3 (37.5)	1 (12.5)	1 (8.3)	0	0	1 (25.0)
Upper respiratory infection	0	0	0	0	0	0	1 (12.5)	0	0	0	0	0
Cough	0	0	0	0	1 (6.3)	1 (6.3)	0	0	0	0	0	0
Colporrhagia	0	0	0	0	0	0	0	0	0	1 (10.0)	0	0
Myalgia	0	0	0	0	0	0	0	0	0	1 (10.0)	0	0

^aN, number of subjects analyzed; n, number of subjects. TEAE, treatment-emergent AE; WBC, white blood cell; RBC, red blood cell.